Clinical Trials Sponsored by MAPS Europe B.V.

Total 216 results

MAPS Europe B.V.
Multidisciplinary Association for Psychedelic Studies

Completed

Open Label Study of MDMA-assisted Psychotherapy for Treatment of PTSD With Optional fMRI Sub-Study

PTSD

Czechia, Germany, Netherlands, Norway, United Kingdom
Medical Enterprises Europe B.V.

Withdrawn

SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I (SHTC-EUROPE-1)

Neoplasms | Urologic Neoplasms | Urogenital Neoplasms | Neoplasms by Site | Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Neoplasms
Medical Enterprises Europe B.V.

Withdrawn

RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)

Bladder Cancer
Refocus Ocular Europe, B.V.

Completed

Trial of the PresView Implant for the Improvement of Near Vision in Presbyopic Patients

Presbyopia

United Kingdom
Aeon Astron Europe B.V.

Unknown

Comparative Study of Ologen Collagen Matrix Versus Mitomycin-C in Trabeculectomy: A Study in Germany

Open-angle Glaucoma

Germany
Medical Enterprises Europe B.V.

Terminated

Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer

Neoplasms | Urologic Neoplasms | Neoplasms by Site | Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Neoplasms | Urinary Bladder Cancer | Malignant Tumor of Urinary Bladder

Austria, Israel, Italy, Netherlands
Terumo Europe N.V.

Recruiting

Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Patients (NAGOMI COMPLEX)

Cardiovascular Disease | Ischemic Heart Disease | Coronary Artery Occlusion

Switzerland, Spain, Belgium, Ireland, Netherlands, France, Austria, Serbia, Sweden, United Kingdom, Italy, Estonia, Poland
Terumo Europe N.V.

Active, not recruiting

Prospective Multicenter Study to Confirm the Performance of the Renzan Stent in Treatment of SFA/POP Artery Disease (PRIZER)

Superficial Femoral Artery Disease | Popliteal Artery Disease

Spain, Belgium, Germany, France, Netherlands
Terumo Europe N.V.

Completed

Holmium-166 Retrospective Collection of Real-World Data (RECORD)

Hepatocellular Carcinoma | Metastatic Cancer

Netherlands, Germany, Switzerland, Belgium, Spain, Portugal, Italy
Terumo Europe N.V.

Terminated

QuiremSpheres Observational Study (Hope166)

Liver, Cancer of, Non-Resectable

Netherlands, Germany
Terumo Europe N.V.

Completed

Safety and Efficacy Study of Kaname Coronary Stent System for the Treatment of Patients With Coronary Artery Disease (KARE)

Coronary Artery Disease | Angioplasty, Transluminal, Percutaneous Coronary

Spain, Germany, Serbia, France, Italy
Terumo Europe N.V.

Completed

Safety and Efficacy of TCD-10023 (Ultimaster) Drug-eluting Stent in STEMI Patients - MASTER Study (MASTER)

Acute ST Segment Elevation Myocardial Infarction

Brazil, Serbia, Italy, Spain, Macedonia, The Former Yugoslav Republic of
Terumo Europe N.V.

Completed

Assessment of the Manageability and Safety of ADBLOCK Adhesion Barrier System in Laparoscopic Gynaecological Surgery (ADBEE)

UTERINE MYOMAS

Germany
Nipro Europe N.V.

Completed

In Vivo Evaluation of the Nipro Elisio™ Dialyzer

Chronic Kidney Disease

France
Terumo Europe N.V.

Recruiting

Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma. (HOMIE-166)

Hepatocellular Carcinoma

Germany
Terumo Europe N.V.

Completed

e-NOBORI Observational Registry of Nobori DES (e-NOBORI)

Coronary Artery Disease

Ireland, France, Taiwan, Spain, United Kingdom, Israel, Netherlands, Czechia, Sweden, Bangladesh, Russian Federation, Brazil, Bulgaria, Serbia, Chile, Germany, Hungary, Indonesia, Georgia, Austria, Belarus, Denmark, Egypt, Estonia, Latvia, Lithuan... and more
Terumo Europe N.V.

Unknown

Prospective, Single-arm, Multi Centre Observations Ultimaster Des Registry (e-Ultimaster)

Coronary Artery Disease

Netherlands, France, United Kingdom, Austria, Ireland, Spain, Bulgaria, South Africa, Israel, Hungary, Switzerland, Chile, Belgium, Japan, Argentina, Portugal, United Arab Emirates, Serbia, Malaysia, Brazil, India, Poland, Indonesia, ... and more
Terumo Europe N.V.

Completed

Optical Frequency Domain Imaging (OFDI) Assessed Strut Coverage of New Terumo DES (DISCOVERY123)

Coronary Artery Disease

France, Netherlands, Germany
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants (Himalayas)

Anemia in Incident Dialysis Patients

Russian Federation, Bulgaria, Thailand, United States, Argentina, Chile, Colombia, Korea, Republic of, Latvia, Malaysia, Mexico, Poland, Romania, Taiwan, Ukraine
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

CKD Anemia

United States, Australia, Thailand, Korea, Republic of, Malaysia, Mexico, Taiwan, New Zealand, Argentina, Chile, Colombia, Hong Kong, Peru, Philippines, Puerto Rico, Singapore
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

CKD Anemia in Stable Dialysis Patients

United States, Puerto Rico
Terumo Europe N.V.

Recruiting

BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC) (BIOPEARL-ONE)

Hepatocellular Carcinoma Non-resectable

Belgium, Italy, Germany, France
Terumo Europe N.V.

Completed

Treatment of Patients With Lesions in the Superficial Femoral and/ or Popliteal Arteries Using Kanshas Paclitaxel-coated Balloon Catheter. (KANSHAS-1)

Peripheral Artery Disease | Femoropopliteal Occlusive Disease

Belgium, Germany
Terumo Europe N.V.

Completed

Prospective Single Arm CAS - ROADSAVER Study (ROADSAVER)

Carotid Artery Stenosis

Belgium, Spain, Czechia, France, Serbia, Netherlands, Germany, Hungary, North Macedonia, Latvia, Poland, Portugal, Slovakia
Terumo Europe N.V.

Completed

Post-Market Clinical Investigation of the FemoSeal™ VCS: A Prospective, Multi-Center Observational European Study (FEMOSEAL CLOSE)

Peripheral Vascular Disease | Hemostasis | Vascular Closure | Endovascular Procedure

Belgium, France, Germany
Terumo Europe N.V.

Withdrawn

BioPearl™ Microspheres Loaded With Doxorubicin: Prospective, Single Arm, Multi-centre Post-market Follow-up Study. (BIOPEARL-FIRST)

Hepatocellular Carcinoma

Belgium
Terumo Europe N.V.

Completed

LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable HCC (PARIS Registry)

Hepatocellular Carcinoma

Belgium, France
Terumo Europe N.V.

Terminated

Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis-HTN Registry (Iberis)

Resistant Hypertension

Serbia, Spain
Terumo Europe N.V.

Unknown

Rapid Exchange Devices Observational Registry. (RXRegistry)

Peripheral (Lowr Extremity) Arterial Disease.

Spain, Belgium
Terumo Europe N.V.

Completed

Randomized Study to Assess the Effect of ThRombus Aspiration on Flow Area in STEMI Patients (TROFI)

Myocardial Infarction | Coronary Artery Disease | STEMI

Germany, France, Denmark, Netherlands
Bayer
Biogen Netherlands B.V; Novartis Europharm Limited; Merck Europe B.V.

Active, not recruiting

An Observational Study to Learn About the Interferon-beta Exposure of Pregnant Women During the Second and Third Trimester in Finland and Sweden (INFORM)

Multiple Sclerosis (MS)

Sweden, Finland
ECRI bv
Terumo Europe N.V.; Abbott Medical Devices

Completed

ABSORB STEMI: the TROFI II Study

Acute ST Segment Elevation Myocardial Infarction

Denmark, Netherlands, Spain, Switzerland
Astellas Pharma Europe B.V.

Completed

Long Term Study of Solifenacin Succinate and Tamsulosin Hydrochloride Oral Controlled Absorption System (OCAS) in Males With Lower Urinary Tract Symptoms (Neptune II)

Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia

Belgium, Italy, France, Austria, United Kingdom, Netherlands, Poland, Slovakia, Belarus, Germany, Czechia
Astellas Pharma Europe B.V.

Completed

Study of Solifenacin Succinate and Tamsulosin Hydrochloride OCAS in Males With Lower Urinary Tract Symptoms (Neptune)

Lower Urinary Tract Symptoms | Benign Prostatic Hyperplasia

Belgium, Italy, France, Austria, United Kingdom, Netherlands, Hungary, Russian Federation, Poland, Slovakia, Belarus, Czechia, Germany
Astellas Pharma Europe B.V.

Completed

A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects

Healthy Volunteers

United States
Astellas Pharma Europe B.V.

Completed

A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis (SERENITY)

Interstitial Cystitis | Bladder Pain Syndrome

Spain, Russian Federation, Belgium, Czechia, Germany, Hungary, Latvia, Netherlands, Poland, United Kingdom
Astellas Pharma Europe B.V.

Completed

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (SYNERGY II)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

Belgium, Russian Federation, Korea, Republic of, United States, Germany, Spain, Australia, Bulgaria, Canada, Czechia, Denmark, Estonia, Finland, Hungary, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, ... and more
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease

Healthy Subjects | Type 2 Diabetes Mellitus (T2DM) | Chronic Kidney Disease (CKD) | Pharmacokinetics of ASP8232 | Pharmacodynamics of ASP8232

Bulgaria, Moldova, Republic of, Romania
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME) (VIDI)

Diabetes Mellitus | Diabetic Macular Edema

United States
Astellas Pharma Europe B.V.

Completed

Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder (Blossom)

Urinary Bladder, Overactive

Belgium, Germany, Spain, Sweden, United Kingdom, Czechia
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder

Overactive Bladder | Pharmacokinetics of Mirabegron | Neurogenic Detrusor Overactivity

Belgium, Denmark, Norway, Poland, Serbia
Astellas Pharma Europe B.V.

Completed

A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin

Type 2 Diabetes Mellitus

Germany
Astellas Pharma Europe B.V.

Completed

An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian Federation

Advanced Prostate Carcinoma

Russian Federation
Astellas Pharma Europe B.V.

Completed

A Combined Single and Multiple Ascending Dose Study of ASP6858 in Healthy Subjects

Healthy Volunteers

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery (ONYX-3)

Venous Thromboembolism | Arthroplasty, Replacement, Hip

Denmark, Spain, United States, Austria, Colombia, Russian Federation, India, Italy, United Kingdom, Germany, Hungary, Estonia, Romania, South Africa, Israel, Poland, Sweden, Canada, Australia, Lithuania, Ukraine, Latvia, Finland, Brazil, Slovak... and more
Astellas Pharma Europe B.V.

Completed

A Study to Investigate the Effect of Oral Doses of Pilocarpine on Salivary Secretion and Static Pupillometry in Healthy Subjects

Healthy Subjects

United Kingdom
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects

Pharmacokinetics of ASP1707 | Pharmacodynamics of ASP1707

France
Astellas Pharma Inc
Astellas Pharma Europe B.V.

Completed

A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR) (SOLAR)

Overactive Bladder | Urinary Incontinence | Urge Incontinence

France, Belgium, Spain, Turkey, Australia, Russian Federation, Hungary, Italy, Netherlands, Poland, Czech Republic
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate Whether Verapamil Has an Effect on the Uptake and Elimination of Solifenacin and Tamsulosin When Administered in a Combination Tablet

Healthy Subjects | Drug-Drug Interaction (DDI)

France
Astellas Pharma Europe B.V.

Completed

A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin

Healthy Subjects | Pharmacokinetics | EC905

United Kingdom

Clinical Trials Sponsored by MAPS Europe B.V.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations